What is the 13F Pro Quality Score for SNTI?

13F Pro ranks Senti Biosciences Holdings, Inc. (SNTI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SNTI's current score at https://13fpro.ai/research/SNTI (free sign-up required for the full ranking).

Where does 13F Pro source SNTI data?

All Senti Biosciences Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Senti Biosciences Holdings, Inc. files with the SEC under CIK 1854270. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SNTI in?

Senti Biosciences Holdings, Inc. (SNTI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SNTI research updated on 13F Pro?

SNTI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Senti Biosciences Holdings, Inc.(SNTI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1854270 SNTI stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $4.3M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

SNTI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Senti Biosciences Holdings, Inc. (SNTI), a Healthcare sector company. SNTI is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $4.3m in revenue. Based on the latest XBRL financial filings (Q1 2026), Senti Biosciences Holdings, Inc. reports quarterly revenue of $16.0K, net income of $-4.2M, free cash flow of $-7.5M. Top institutional holders of SNTI by reported 13-F value include NEA Management Company,, Nantahala Capital Management,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. SNTI trades on the Nasdaq exchange and files with the SEC under CIK 1854270. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SNTI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Senti Biosciences Holdings, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$16.0K

Net Income

Q1 2026

$-4.2M

Free Cash Flow

Q1 2026

$-7.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-99.1% YoY

$22.0KFY 2025

FY22 $4.3MFY23 $2.6MFY25 $22.0K

Net Income

+13.5% YoY

$-61.4MFY 2025

FY22 $-58.2MFY23 $-71.1MFY25 $-61.4M

Operating Income

+25.8% YoY

$-68.8MFY 2025

FY22 $-62.1MFY23 $-92.7MFY25 $-68.8M

EPS (Diluted)

-70.5% YoY

$-2.73FY 2025

FY22 $-0.22FY23 $-1.60FY25 $-2.73

Total Assets

-57.1% YoY

$51.2MFY 2025

FY22 $180.8MFY23 $119.5MFY25 $51.2M

Op. Cash Flow

+17.1% YoY

$-43.4MFY 2025

FY22 $-34.9MFY23 $-52.4MFY25 $-43.4M

Metric	FY 2025	FY 2023	FY 2022
Revenue	$22.0K -99.1%	$2.6M -40.2%	$4.3M
Net Income	$-61.4M +13.5%	$-71.1M -22.1%	$-58.2M
Operating Income	$-68.8M +25.8%	$-92.7M -49.4%	$-62.1M
EPS (Diluted)	$-2.73 -70.5%	$-1.60 -617.9%	$-0.22
Total Assets	$51.2M -57.1%	$119.5M -33.9%	$180.8M
Operating Cash Flow	$-43.4M +17.1%	$-52.4M -50.1%	$-34.9M

AI Insight: SNTI Financial Trends

Senti is a pre-revenue biotech burning cash at a sharply decelerating rate; equity has collapsed from $44M to $3M in less than two years.

• Operating cash burn narrowed to $7M in Q1 2026 from $14M in Q4 2024, a 50% improvement despite persistent negative operating income.

• Net losses compressed to $4M in Q1 2026 from $29M in Q3 2024, signaling tighter cost discipline across the company.

• Stockholders' equity eroded 93% from $44M in Q2 2024 to $3M in Q1 2026, reflecting sustained operating losses and likely capital raises.

⚠ Equity base of $3M leaves minimal buffer for additional losses; any quarterly burn >$3M forces immediate financing or insolvency.

⚠ No revenue materializing across 9 quarters suggests clinical/regulatory delays; path to profitability remains undefined.

AI Insight: SNTI Ratio Trends

Senti Biosciences remains unprofitable with sparse operational metrics; ROA showed modest improvement to -44.1% in Q1 2026 but remains deeply negative.

• ROA deteriorated significantly from -2.5% in Q4 2024 to -68.2% in Q1 2025, then improved to -44.1% in Q1 2026.

• Operating margin, net profit margin, ROIC, and D/E ratios absent across all periods; limited visibility into operational efficiency.

⚠ ROE deteriorated from -9.5% in Q4 2024 to -149.1% in Q1 2025; recovery trajectory unclear despite Q1 2026 data gap.

⚠ Persistent negative returns (ROA, ROE) indicate ongoing losses; cash burn and path to profitability remain opaque.

Get alerted when SNTI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Senti Biosciences Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SNTI

NEA Management Company, LLC
$3.1M3,775,615 sh
Nantahala Capital Management, LLC
$721.1K888,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$436.5K537,504 sh
GEODE CAPITAL MANAGEMENT, LLC
$168.1K207,043 sh
VANGUARD FIDUCIARY TRUST CO
$74.0K91,193 sh
Menlo Ventures Management, L.P.
$29.0K35,737 sh
BlackRock, Inc.
$20.4K25,074 sh
XTX Topco Ltd
$14.0K17,277 sh
NORTHERN TRUST CORP
$13.6K16,778 sh
STATE STREET CORP
$8.1K10,010 sh

Fund	Value	Shares
NEA Management Company, LLC	$3.1M	3,775,615
Nantahala Capital Management, LLC	$721.1K	888,000
VANGUARD CAPITAL MANAGEMENT LLC	$436.5K	537,504
GEODE CAPITAL MANAGEMENT, LLC	$168.1K	207,043
VANGUARD FIDUCIARY TRUST CO	$74.0K	91,193
Menlo Ventures Management, L.P.	$29.0K	35,737
BlackRock, Inc.	$20.4K	25,074
XTX Topco Ltd	$14.0K	17,277
NORTHERN TRUST CORP	$13.6K	16,778
STATE STREET CORP	$8.1K	10,010

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SNTI on your watchlist

Track score changes the day Senti Biosciences Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SNTI a good stock to buy?

13F Pro's AI-powered analysis of Senti Biosciences Holdings, Inc. (SNTI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SNTI are available on the SNTI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SNTI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SNTI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Senti Biosciences Holdings, Inc.'s investment landscape.